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IA is increasingly prevalent and problematic among patients with 
immunodeficiency. Early diagnosis of IA can be difficult because the symptoms 
patients display are not specific to fungal infections, and the diagnostic tests 
currently in use are unreliable. It is well known that the organisms that cause IA 
shed protein antigens into body fluids once inside the host. In previous studies, 
our lab detected PPIase, Eglc, Ecm33, TrxR and CatB in IA mouse serum and 
urine, using an antigen discovery platform. In our current work, we seek to 
develop mAbs that specifically target PPIase, Eglc, Ecm33, TrxR and CatB as an 
effective diagnostic tool for the invasive fungus Aspergillus fumigatus. rPPIase, 
rEglC and rCatB were purified from bacterial cultures. rPPIase and rCatB were 
emulsified in TiterMax® Gold adjuvant (CytRx Corporation, Los Angeles, CA) and 
used to immunize BALB/c mice. The rPPIase emulsion elicited a robust immune 
response (high titers) which was confirmed via ELISA. The rPPIase immunized 
mice that had the highest titers were then boosted with recombinant protein in 
preparation for a splenocyte and myeloma fusion to produce a hybridoma cell 
line. A mAb was then selected and derived with high specificity and sensitivity for 
rPPIase. The long term goal is to produce high quality anti-PPIase, anti-Eglc, 
anti-Ecm33, anti-TrxR and anti-CatB mAbs as candidates for IA diagnostic tests, 
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Aspergillus. The saprophytic fungal species, Aspergillus, are primarily found in 
soil, dust, flora decomposition, and other decaying organic material in nature. In 
this habitat, the fungi biotically decompose the organics releasing carbon and 
nitrogen back into the surrounding environment (9, 32).  Many Aspergillus 
species have the ability to readily break down basic, biological elements such as 
proteins, saccharides, and fatty acids as well as more specific compounds such 
as xylene, pectin, and cellulose and thus do not require specific nutrients to 
survive (29). The fungus is also pervasive in a large spectrum of environments as 
a result of airborne dispersal by natural mechanical disturbances, such as wind, 
and human agitation of compost and sewage (53, 54). Asexual spores, known as 
conidia, are the fungal reproductive units that disseminate into the atmosphere 
for propagation. The conidia, produced by conidiophore vesicles in the mycelium, 
are linked together in the conidiophore stalk by a disjunctor and carried from the 
apex of the conidiophore, by basipetal growth, where they reside until dispersed 
(17, 51). Different Aspergillus species have conidia that vary in size. For 
example, A. niger and A. flavius produce larger conidia (3-5.0 µm) and A. 
fumigatus (A. fum) smaller conidia (2-3.5µm) (31, 64). Because of the 
hydrophobicity and size of the A. fum conidia, they can remain suspended in air 
for prolonged periods of time allowing easy access into the pulmonary alveoli of 
the lungs, while the larger conidia of A. niger and A. flavius tend to settle in the 
paranasal sinuses and upper respiratory tract of humans (6, 30, and 58). 





Aspergillus, most of which are non-pathogenic (25). Pathogenic species of 
Aspergillus to humans include A. flavus, A. niger, A. terreus, A. nidulans, and A. 
fumigatus.  
 
Aspergillus fumigatus. A. fum is a filamentous fungus that grows rapidly, on 
nutrient rich media, reaching colony diameters of 5-7cm at room temperature 
(RT) after 10 days. The colonies can range in appearance having a velutinous 
(velvet) to arenaceous (powdery) texture and can contain different colors such as 
white, green, blue-green, yellow, and brownish-red with a sporulation boundary 
that is generally white. The fungal condiophores consist of a 20-30µm diameter 
head and stalk that together are 300µm in length, and the conidia radiate in a 
dense, column-like fashion from the head of the condiophore (31). The 
thermotolerant A. fum thrive in high humidity at 37°C, which is typical of its niche 
environment, and can tolerate temperatures exceeding 50°C (18, 56). Most other 
pathogenic species of Aspergillus, like A. flavus and A. niger, can germinate and 
produce hyphae at 37°C, but tend to proliferate much better at temperatures near 
30°C. A. fum grown in human sera, which contains albumin, exhibits increased 
mycelial growth and conidial germination in vitro. This suggests that the 
temperature and conditions, within the human body, correlate to ideal 






 Although most people inhale an estimated 200 A. fum conidia each day, 
immunocompetent persons seldom are affected by the spores as a result of 
mucociliary clearance and a functional innate immune response. A. fum is an 
opportunistic pathogen, thus the population demographic most at risk for IA are 
acutely immunocompromised individuals (14). A. fum is the most prevalent 
etiological determinant of all pathogenic Aspergillus species, and is responsible 
for an estimated 90% of all human Aspergillus infections (7, 23, 42, and 69). 
 
Human Immune Response to A. fum Ingress and Morphology. Inhalation of 
A. fum conidia is the most common route of entry into the human body. When A. 
fum conidia reach the alveoli or bronchial mucosa of an immunocompetent 
individual, they are typically cleared by the mucosa or destroyed by the alveolar 
macrophages via the release of reactive oxygen intermediates (ROI) to the 
phagosomes containing the conidia (63). Polymorphonuclear leucocytes 
(PMNLs) and platelet cells have also been observed in preventing conidia from 
germinating inside the host and eventually manifesting an infection (8, 62). In 
addition to the innate immune response, epithelial cells produce antimicrobial 
peptides (defensins, lysozyme, lactoferrin and surfactant proteins) in respiratory 
secretions that contribute resistance to A. fum infections. The surfactants perform 
a task resembling opsonins and stimulate the release of modulating inflammatory 





the environment, limiting the supply to the conidia which is necessary for 
germination (78, 87).  
 
If the A. fum conidia is not eliminated or inhibited by these first lines of defense, 
then they with begin to germinate. The warm, moist, and nutrient dense 
environment of the alveolar space, similar to that of organic compost, prompt the 
germination process in which the conidia begin polar growth and mitotic nuclear 
division. During mitosis, septi are dispersed along the elongating hyphae that 
result in filamentous growth completing the transformation of unicellular conidia 
to multicellular hyphae (55). The A. fum multicellular hyphae are now in the 
morphotypic form that is conducive to invasion of the tissue.  
 
Invasive Aspergillosis (IA). Invasive aspergillosis (IA), probably the most 
severe Aspergillus-associated infection, normally occurs when the host’s immune 
defenses become impaired or incompetent. A predisposition to IA infection is 
commonly seen among patients of extensive corticosteroid treatment, leukemia, 
lymphoma, neutropenic patients, graft-versus-host disease, hematopoietic stem 
cell or solid organ transplants, chronic granulomatous disease, and HIV (22, 39, 
48, 52, 59, and 85).  A. fum has become the most prevalent airborne pathogen, 
as of recent, and is responsible for serious and often fatal infections in 
immunocompromised patients in developed countries because of the advent of 





rate from IA, according to patient population surveys, is 5-24% incident (region 
dependent) and 30-40% fatal in acute leukemia patients, 10% incident and 60% 
fatal in allogeneic haematopoietic stem cell transplants, 11-14% incident and 50-
60% fatal in solid organ transplants, and 12% incident and 70-85% fatal in AIDS 
and alemtuzumab patients, burn victims, and general immunosuppressed 
patients in the ICU (22, 34, 48, 49, 60, 73, 79, and 80).  
 
Patients who are neutropenic for extended periods of time, specifically those 
treated with cyclophosphamide, have the highest risk for IA (4, 76). 
Cyclophosphamide is a DNA-alkylating agent used to treat transplant and 
hematological diseased patients that also impedes cellular replication which 
diminishes white blood cell and neutrophil levels circulating in the bloodstream. 
IA in neutropenic patients is characterized by thrombosis and hemorrhaging due 
to the rapid and pervasive growth of A. fum hyphae (15, 76). The hyphae, as well 
as the conidia, have been observed activating platelets in vitro and is thought to 
be a contributor to thrombosis (64). Neutropenic patients continue to produce 
tumor necrosis factor alpha (TNF-α), yet they are deficient in inflammatory 
infiltrates, resulting in a deficient inflammatory response. If appropriate 
neutrophils levels are not restored, then IA often results in angioinvasion and 
dissemination of the infection to circumferential organs via the bloodstream (19). 
A particularly dangerous spread of IA to other organs is the dissemination of 





barrier.  This form of IA, called CNS aspergillosis, is characterized by 
parenchymal abscesses and the presence of A. fum in cerebrospinal fluid (CSF). 
This form of IA is often fatal because most anti-fungal drugs cannot effectively 
pass the blood-brain barrier and the patient already lacks the necessary immune 
cells in the CSF (70).    
 
Non-neutropenic patients are also at risk for IA, but for pathologically different 
reasons than that of neutropenic patients. Examples of non-neutropenic patients 
at risk for IA are allogeneic transplant, prophylaxis and graft-versus-host disease 
patients that receive prolonged corticosteroid treatment. IA in these patients is 
characterized by inordinate inflammation, tissue necrosis, and 
pyroglanulomatous infiltrates. Corticosteroids inhibit phagocytosis, phagocyte 
lysis via ROI, and production of cytokines and chemokines, thus hindering the 
phagocytes from effectively destroying A. fum conidia and hyphae (47). These 
patients, unlike the neutropenic, retain high neutrophil counts that prevent the 
infiltration of hyphae into lung tissue, but tissue damage is still incurred due to a 
severe inflammatory response. Cause of death in these patients is usually a 
result of the excessive inflammation and not unrestricted fungal growth (19).     
 
Symptoms and Current Diagnostics for IA Infections. IA infections are most 
often seen in the sinopulmonary tract, as inhalation of A. fum spores is the 





to pulmonary infarction and hemoptysis (72). If the infection reaches the CNS, 
seizures and stroke can occur. IA diagnoses can be difficult depending on the 
patient type and the diagnostic method employed, thus a diagnosis may be 
labeled as probable or positive with the understanding that a positive diagnosis 
may not be completely conclusive. If a histological determination of invasive 
hyphae can be shown or a positive culture procured from a typically sterile 
sample, such as pleural fluid, then the IA is diagnosed as positive. If common risk 
factors associated with IA are present in the patient, such as long-term 
neutropenia or immunosuppressive therapy, and clinical symptoms occur, then 
the diagnosis may be labeled probable (21). Making a timely diagnosis of IA 
infections is often more problematic for patients who do not have a hematological 
disease. The original methods of diagnosing IA were developed in hematology 
patients, which rely on histological signs of tissue invasion and radiological 
analysis (35). Lung CT scans of IA patients often reveals nodules with halo-like 
appearance that can be indicative of angioinvasive pulmonary mycosis, but this 
diagnosis is not specific to infections caused by A. fum and it is almost always 
used as a diagnosis for neutropenic patients (12).  Also, children with IA 
generally do not display the halo-like nodules in lung tissue (10).  
 
Culturing A. fum from brochoalveolar lavage fluid (BALF) is another diagnostic 
that is employed, but the upper limit of sensitivity for this diagnostic is about 50% 





beta-D-glucan and galactomannan (GM). The beta-D-glucan assay has 77% 
sensitivity and 85% specificity, but it is also cross-reactive with Candida, 
Scedosporium, Fusarium and Pneumocystis species (38). The serum GM ELISA 
assay has been reported to have good diagnosis accuracy among the spectrum 
of IA patient groups with 71% sensitivity and upwards of 89% specificity, however 
the specificity is diminished by beta-lactam antibiotics, gluconate based I.V. 
fluids, piperacillin, tazolbactam, and agents that are mould active (83, 45). PCR 
detection of IA in whole blood and serum has 75% sensitivity and 87% specificity. 
IA PCR diagnostics are also relatively inexpensive, can detect specific fungal 
species based on genetic composition, and give rapid results. The drawback to 
PCR based diagnostics are ubiquitous environmental fungal DNA contamination, 
lack of ability to differentiate between fungal disease and colonization, the use of 
sophisticated equipment with a knowledgeable operator, and a lack of portability 
(26). Lateral flow diagnostic devices (LFDs) have also been proposed as a 
simple, rapid, reliable, cost-efficient, and non-invasive diagnostic for IA detection 
(84). LFD diagnostics for IA are still in the development phase, but are proving to 
be a promising diagnostic tool.               
      
mAb Detection of A. fum proteins. Initial therapy antifungal medications for IA 
infections have significantly improved from the use of drugs such as amphotericin 
B deoxycholate (AmB-D) having a survival rate of 58% in randomized clinical 





standard for primary therapy of IA, having a survival rate of 71% in randomized 
clinical trials with a successful outcome rate of 53% (34, 82). Though there have 
been great advancements in antifungal medications effective against IA, there 
has not been definitive gold standard diagnostic for IA. A rapid and reliable IA 
diagnosis is crucial, as delay severely worsens the chance of a favorable 
outcome when positive identification of infection and effective treatment have not 
been administered.  
 
Much of the focus on mAb based immunodiagnostics for IA has been GM based 
detection and there are commercially available diagnostics with mAbs against 
this particular antigen (44, 61). mAb detection assays of A. fum GM, like the use 
of mAb EB-A2 in ELISA format, were reported have specificity consistently 
greater than 85%, but a highly variable sensitivity ranging from 29%-100% (81). 
mAbs against GM, like EB-A2, are problematic in that they have been attributed 
with having cross-reactivity with galactoxymannan from Peniccillium GM, GM in 
food and drinks, lipoteichoic acid in bifidobacteria, and cyclophosphamide (2, 20, 
33, 50, and 81). Because of these problems associated with GM mAb detection 
assays, there is a need for IA immunodiagnostic tests that utilizes mAbs aimed 
against alternate epitopes. 
 
To address the need for mAbs directed against GM alternative epitopes, for 





Microbial Antigen Discovery (InMAD) to screen for potential antigen targets 
circulating in serum, specifically mouse and guinea pig serum (57). Using this 
technique, our lab discovered a series of circulating immunogenic proteins and 
prioritized the list of protein antigens based on their immunogenicity (13). The 
candidates that we chose to pursue as potential A. fum antigen targets for mAb 
production were peptidyl-prolyl cis-trans isomerase (PPIase), glucan endo-1,3-
beta-glucosidase (Eglc), Extracellular mutant protein 33 (Ecm33), thioredoxin 
















Materials and Methods 
Plasmids and Primers. The DNA primers, synthesized by IDT, and plasmid 
vectors used in DNA constructs are listed in Tables 1 & 2.  
 
Addition of Flanking Elements via Polymerase Chain Reaction (PCR). A 
Hind III R.E. recognition site and a 6x-adenine S. cerevisiae, kozak consensus 
sequence, were added to the 5’ terminus of PPIase and TrxR via PCR (37) using 
the forward primers specified in Table 2. A coagulation factor Xa protease 
(Factor Xa) recognition site (ATTGAAGGTCGT), followed by 2x adenines and a 
Not I R.E. recognition site, were added to the 3’ terminus via PCR by the primers 
detailed in Table 2. The addition of all the same flanking elements to EglC, 
Ecm33 and CatB, with the exception of a 5’ Kpn I R.E. recognition site on CatB, 
was attempted via PCR using the specified primers in Table 2. The Platinum® 
PCR SuperMix High Fidelity (Life Technologies™, Carlsbad, CA) protocol was 
used for the PCR addition of flanking elements according to the manufacturer’s 
specifications. 10pmoles of PPCTI-F-H3Koz, PPCTI-R-N1Xa, THIORED-F-
H3Koz, THIORED-R-N1Xa primers were used in the PPIase and TrxR PCR 
addition reactions respectively. 250ng of PPIase and TrxR DNA template were 
added to their respective mix of primers and Platinum® PCR SuperMix High 
Fidelity for a 50µL total volume. The thermocycler parameters for the flanking 





94°C for 5m, 68°C for 30s, 72°C for 2m30s with 30 cycles; 72°C for 10m with 1 
cycle; 8°C on hold.  
 
Academic and Commercially Obtained Constructs. Constructs of PPIase, 
CatB, Eglc, Ecm33, and TrxR, in pQE-30Xa were obtained from Scott G. Filler 
M.D.(Harbor UCLA).  
 
PPIase and TrxR gene constructs, intended for ligation into pYES3/CT recipient 
plasmid, were assembled via polymerase chain reaction (PCR) addition of 
flanking elements. Ecm33, EglC, and CatB were codon optimized for S. 
cerevisiae, synthesized, and ligated into their respective plasmid cloning vectors 
(Ecm33 into pUCIDT, EglC into pIDTBlue, and CatB into pIDTBlue) by Integrated 
DNA Technologies (IDT).  
 
PPIase and TrxR constructs were codon-optimized and synthesized by 
NeoBioLab for protein production in S. cerevisiae. The IDT S. cerevisiae codon 
optimized EglC, Ecm33 and CatB gene constucts were sent to NeoBioLab for 






Agarose Gel Electrophoresis. The agarose gel electrophoresis protocol (71), 
used for DNA analysis, was  conducted with 1% agarose gels containing 10ug of 
EtBr, run at 115v for approximately 1hr., and imaged on a Gel Doc™ XR System 
(Bio-Rad, Hercules, CA) via UV fluorescence in the EtBr dropdown settings. All 
1% agarose gel images were exported as a publication quality .jpg file using 
Image Lab™ Software (Bio-Rad, Hercules, CA). 
 
Sub-cloning Digest and Purification of Gene Constructs and pYES3/CT. 1µg 
of Qiagen Plasmid Maxi Kit (Qiagen, Netherlands) purified TrxR, EglC, PPIase 
gene constructs and pYES3/CT were digested with Hind III and NotI using NEB 
Restriction Enzyme Double Digest Protocol with Standard Restriction Enzymes 
(New England BioLabs®, Ipswich, MA). The digests were then run on a 1% 
agarose gel and imaged at the previously specified parameters. The linear bands 
of pYES/CT vector and the gene construct with Hind III and Not I sticky-ends, 
were cut  and purified from the 1% agarose using a QIAquik Gel Extraction Kit 
(Qiagen, Netherlands) according to the manufacturer’s specifications. All purified 
digests were eluted in 30 µL of ddH2O. Purified pYES3/CT and gene constructs 
were then quantified by a SmartSpec™ Plus spectrophotometer (Bio-Rad, 






Gene Construct Ligations into pYES3/CT. TrxR, EglC, and PPIase gene 
constructs, with Hind III and Not I sticky-ends, were ligated into YES3/CT using 
the Instant Stick-end Ligase Master Mix Protocol (New England BioLabs®, 
Ipswich, MA) according to the manufacturer’s specifications. 
 
Restriction Analysis of Recombinant pQE-30Xa Plasmids. EglC in pQE-30Xa 
(EglC-pQE-30Xa) was digested with NcoI, which cut once inside the gene and 
once in the vector, and HindIII, which also cut once in the vector. Ecm33 in pQE-
30Xa (Ecm33-pQE-30Xa) was digested by KpnI which made a cut in both the 
vector and the gene. TrxR in pQE-30Xa (TrxR-pQE-30Xa) was cut once in the 
vector by HindIII and once inside the gene by EcoRV. PPIase in pQE-30Xa 
(PPIase-pQE-30Xa) was digested with NcoI, which cut once inside the gene and 
once in the vector, and HindIII, which also cut once in the vector. CatB in pQE-
30Xa (CatB-pQE-30Xa) was digested with HindIII which cut three times inside 
the gene and once in the vector. 1µg of each Qiagen Plasmid Maxi Kit (Qiagen, 
Netherlands) purified gene construct in pQE-30Xa was digested, with the 
mentioned R.E.’s, using NEB Restriction Enzyme Double Digest Protocol with 
Standard Restriction Enzymes (New England BioLabs®, Ipswich, MA). The 







Yeast and Bacterial Lysis. Yeast cells need to be lysed by mechanical 
disruption of the cell wall (Bead beating), disruption by boiling in detergents or 
caustic agents, or by using a combination of both methods. E. coli cells have a 
thin cell wall and thus only require heating in water to lyse them for plasmid DNA 
extraction. In preparation for colony PCR, a NaOH yeast and bacterial boil 
method were performed to extract plasmid DNA from the INVSc1 and NEB 5-
alpha cells transformed with each gene construct in pYES3/CT. Lysis protocols 
for each cell type were adapted from McClean:Colony PCR (E.coli) 
(OpenWetWare.org), and Blackburn:Yeast Colony PCR protocol V2.0 
(OpenWetWare.org) for conditions optimal to our reagents and procedure. An 
individual IVNSc1 yeast colony or NEB 5-alpha colony was selected with a sterile 
loop and placed into 20µL of 20mM NaOH or 20µL of ddH2O respectively, 
incubated at 95°C for 45 min., and centrifuged at 13,000xg for 10min. 1µL of 
crude yeast or bacterial DNA extract was used as template in the colony PCR 
protocol. 
 
 Yeast and Bacteria Colony PCR. Crude supernatant from bacterial or yeast 
lysate, containing plasmid DNA, was used as a template for PCR. The Platinum® 
PCR SuperMix High Fidelity (Life Technologies™, Carlsbad, CA) protocol was 
used for the colony PCR reactions according to the manufacturer’s 
specifications. 10pmoles of pYES3 T7 F and pYES3 R primers were used in all 





and bacterial lysis, was added to their respective mix of primers and Platinum® 
PCR SuperMix High Fidelity for a 50µL total volume. The thermocycler 
parameters for the colony PCR reactions was programmed as follows: 95°C for 
1m with 1 cycle; 95°C for 10s, 55°C for 1m, 72°C for 1m30s with 35 cycles; 72°C 
for 10m with 1 cycle; 8°C on hold.  
 
Sanger Sequencing Analysis of Gene Constructs in pQE-30Xa and 
pYES3/CT. 500ng of template DNA was mixed with 10µM of the appropriate 
primer(s) and was submitted for Sanger sequencing (68). All the sequencing 
primers and their applications are listed in Table 2. All of the Sanger sequencing 
was performed by the Nevada Genomics Center. The resulting sequencing data, 
from each submission, was posted by the Nevada Genomics Center to the 
dnaLIMS server (dnaTools™, Inc.) for retrieval of data files. All files were 
retrieved as trimmed fasta text files. The trimmed fasta sequences were analyzed 
and aligned to the sequences of each gene, flanking element, and sequence of 
pQE-30Xa and pYES3/CT, as determined in the NBCI database, by both 
SnapGene® v2.2.2 and ApE v1.17 DNA analysis software.      
 
M15[pREP4] Transformations and Analysis. 10ng of each construct in pQE-
30Xa was transformed into separate 100µL aliquots of chemically competent 





(Qiagen, Netherlands). 50, 100 and 200µL of the transformed M15[pREP4] cell 
suspensions were plated onto fresh LB-agar plates containing 25µg/mL 
kanamycin (Kan25) and 100µg/mL ampicillin (Amp100) of antibiotic selection, and 
incubated overnight at 37°C. The next day, 8 individual growing colonies were 
picked with a sterile loop, swiped onto a fresh LB-agar-Amp100-Kan25 plate, and 
the loop was placed in 3mLs of liquid LB-Amp100-Kan25 with 250 rpm shaking, 
overnight at 37°C. The final day, a QIAprep spin miniprep (Qiagen, Netherlands) 
was performed on the selected M15[pREP4] colonies. A restriction analysis R.E. 
digest of constructs in pQE-30Xa was performed on the purified plasmid DNA 
and each 50µL digest was run on a 1% agarose gel to screen for colony DNA 
that contained each gene construct in pQE-30Xa. 
 
NEB 5-alpha Transformations and Analysis. The EglC, PPIase, and TrxR 
constructs in pYES3/CT were transformed into 2µL of each ligation reaction mix, 
containing EglC, PPIase, and TrxR constructs in pYES3/CT were transformed 
into NEB 5-alpha E. coli using the NEB 5-alpha Competent E. coli (High 
Efficiency) protocol (New England BioLabs®, Ipswich, MA). 50, 100 and 200µL of 
the transformed NEB 5-alpha cell suspensions were then plated onto fresh LB-
agar-Amp100 plates, incubated overnight at 37°C, and screened the following day. 
10 individual growing colonies were picked with a sterile loop, swiped onto a 
fresh LB-agar-Amp100 plate and the loop was placed in 3mLs of liquid LB-Amp100 





pYES3/CT was performed on the purified plasmid DNA and each colony PCR 
was run on a 1% agarose gel to screen for colony DNA that contained each gene 
construct in pYES3/CT. 
 
Yeast Transformations and Analysis. INVSc1 S. cerevisiae cells, to be used in 
the yeast transformations, were grown overnight at 30°C with shaking at 205rpm. 
The INVSc1 cells were made chemically competent using the S.c. EasyComp™ 
Kit (Life Technologies™, Carlsbad, CA), suspended in kit solution II at a final 
OD600 of 1.0, and divided into 50µL aliquots. 1µg of purified EglC, TrxR, and 
PPIase constructs in pYES3/CT were transformed into 50 µL of chemically 
competent INVSc1 cells using the S.c. EasyComp™ Kit (Life Technologies™, 
Carlsbad, CA) transformation protocol. The transformed cells were then plated 
on SC(-Trp) minimal medium agar plates and incubated at 30°C for 4 days. 
 
Bacterial and Yeast Glycerol Stocks. Glycerol stocks were made from a 
bacterial or yeast clone after the clone was positively identified as one that 
contained a construct of interest. NEB 5-alpha or M15[pREP4] clones were 
streaked on an LB-agar plate with proper selection and incubated overnight at 
37°C. A single colony was selected from the LB agar plate, inoculated into 3mLs 
of LB with proper selection, and incubated at 37°C with shaking at 250rpm until it 





Trp) minimal medium, and incubated at 30°C with shaking at 205rpm until turbid. 
0.5mL of the bacterial or yeast clone culture was mixed with 0.5mL of 50% 
glycerol in a cryogenic screw-cap vial and stored at -80°C. 
 
INVSc1 Yeast Growth and Induction. INVSc1 glycerol stocks containing Eglc, 
TrxR, and PPIase constructs in pYES3/CT were inoculated into 1L of SC(-Trp) 
medium containing 2% glucose and 2% raffinose and grown overnight at 30°C 
with shaking at 205rpm. The cultures were then grown and induced with 2% 
galactose in accordance with the pYES2/CT, pYES3/CT, and pY2/CT Yeast 
expression vectors with C-terminal tags and autotrophic selection markers (Life 
Technologies™, Carlsbad, CA) protein expression protocol. After expression, the 
cultures were centrifuged at 1,500xg for 5 min. at 4°C. The supernatant was 
decanted and the cell pellet was stored at -80°C. 
 
M15[pREP4] Bacteria Growth and Induction. M15[pREP4] glycerol stocks 
containing Eglc, TrxR, Ecm33, CatB and PPIase constructs in pQE-30Xa were 
each inoculated into 1L of LB-Amp100-Kan25 medium and grown to an OD600 of 
0.6 (~3 hrs.) at 37°C, with shaking at 200rpm. Once the cultures reached an 
OD600 of 0.6, then 100µL of 1mM IPTG was added to the culture and incubated 
at 30°C for 4 hrs. After the 4 hr. induction, the cells were centrifuged at 4,000xg 






Recombinant Protein Purification from Bacterial Cytosol in Native 
Conditions. M15[pREP4] clone cultures, previously pelleted, were thawed on ice 
for 15 min. and resuspended in 10mLs of native condition HisPur™ Cobalt 
Equilibration/Wash Buffer (Thermo Fisher Scientific). 1µg of lysozyme and 25U of 
benzonase were added to the resuspended culture, and incubated on ice for 30 
min. Suspension was sonicated at 300W with six 10 sec. bursts. The cytosolic 
lysate was then centrifuged at 10,000xg for 20 min., at 4°C. The cytosolic lysate 
supernatant was purified over a 6x-His tag HisPur™ Cobalt Spin affinity 
chromatography column (Thermo Fisher Scientific) under native conditions. The 
cell debris and I.B. pellet was stored at -20°C. 
 
Recombinant Protein Purification from Inclusion Bodies in Denaturing 
Condition. The cell debris and inclusion body (I.B.) pellet from bacterial cytosol 
purification were resuspended in 25mLs of 1x BugBuster® Protein Extraction 
Reagent (Novagen®) and incubated at room temperature (RT) for 5 min. 150mLs 
of 1/10x BugBuster® was added to suspension and centrifuged at 5,000xg for 
15min., at 4°C. Supernatant was carefully removed with a serological pipette and 
discarded. I.B. and remaining cell debris were resuspended in 12.5mLs of 1/10x 
BugBuster®, and centrifuged at 16,000xg for 15 min., at 4°C. Supernatant was 
carefully removed with a serological pipette and discarded. I.B.’s were 





Buffer, and centrifuged at 27,500xg for 20 min., at 4°C.The I.B. lysate was 
purified over a 6x His-tag HisPur™ Cobalt Spin (Thermo Fisher Scientific) affinity 
chromatography column in denaturing conditions.   
 
Recombinant INVsc1 Clone Protein Purification. Induced INVSc1 yeast 
pellets stored at -80°C were thawed at RT and lysed, under EDTA free 
conditions, in accordance with the pYES2/CT, pYES3/CT, and pY2/CT Yeast 
expression vectors with C-terminal tags and autotrophic selection markers (Life 
Technologies™, Carlsbad, CA) protein expression protocol. The yeast lysate 
supernatant was run over a 6x-His tag HisPur™ Cobalt Spin (Thermo Fisher 
Scientific) affinity chromatography column.  
 
Cytosolic Purified Recombinant Protein and mAb Dialysis. Cytosolic purified, 
positive rPPIase+6xHis and rCatB+6xHis elution fractions from the Cobalt affinity 
columns, were pooled and dialyzed in 4L phosphate-buffered saline (PBS), pH 
7.4 exchanges every 12hrs. for a total of 3 exchanges. The recombinant protein 
was concentrated to 1mL via centrifugal spin filter. The final recombinant protein 
concentration in PBS was determined by bicinchroninic acid assay (BCA) as 
described by Smith, P.K. (74). All  mAb clones were also dialyzed using this 






I.B. Purified Recombinant Protein Dialysis. I.B. purified, positive 
rPPIase+6xHis and rCatB+6xHis elution fractions from the Cobalt affinity 
columns, were pooled and dialyzed in 4L PBS, pH 7.4 exchanges every 12hrs. 
with a down gradient of urea concentrations at every exchange. The first 
exchange contained  4L PBS + 6M urea, the second 4L PBS + 4M urea, the third 
4L PBS + 2M urea, and a final 4L PBS. The recombinant protein was 
concentrated to 1mL via centrifugal spin filter, and the final protein concentration 
was determined by BCA. 
 
6xHis Removal, Purification, and Concentration. Factor Xa is a coagulation 
factor Xa protease which recognizes the amino acid sequence Ile-Glu/Asp-Gly-
Arg˅ and cleaves after the arginine. Affinity purified rPPIase-6xHis and rCatB-
6xHis proteins were dialyzed in three, 2L exchanges of 1x Factor-Xa 
Cleavage/Capture Buffer, pH 6.5 (Novagen®) for 12hrs each. 130U and 21.5U of 
Factor Xa protease were then added to 2mg of rPPIase-6xHis and 477ug of 
rCatB-6xHis, respectively, and incubated for 16hrs. at 25°C, in accordance with 
the Factor Xa Cleavage Capture Kit (Novagen®) protocol. The Factor Xa 
protease was removed from the rPPIase-6xHis and rCatB-6xHis cleavage 
reaction samples using 4mL and 2mL of Xarrest™ Agarose (Novagen®), 
respectively, in accordance with the Factor Xa Cleavage Capture Kit protocol. 





PBS, pH 7.4 for 12hrs each, concentrated via centrifugal spin filter, and the final 
protein concentration was determined by BCA.       
 
SDS PAGE Gels and PDVF Transfer. All SDS PAGE gels and SDS sample 
prep were run on 10% Mini-PROTEAN® TGX™ Precast gels (Bio-Rad, Hercules, 
CA), at 130V for 1hr. using Laemmli SDS-PAGE Protocol (43) in a Mini-
PROTEAN® Tetracell vertical electrophoresis apparatus (Bio-Rad, Hercules, CA). 
All SDS PAGE gels, that were run for a western blot, were transferred to a Trans-
Blot® Turbo™ PVDF membrane in accordance with the Trans-Blot® Turbo™ 
Transfer System (Bio-Rad, Hercules, CA) protocol. 
 
Western Blot Protocol.  Standard western blots were performed for all blots in 
accordance with the Towbin H, Staehelin T, and Gordon J protocol (11, 77). 
TBST-0.05% (Tris-Buffered Saline + 0.05% Tween 20, pH 7.4) was used in all 
washing steps. The overnight blocking steps, primary Ab, and secondary 
antibody dilutions were done in Blocking buffer (TBST-0.05% + 5% skim milk). All 
western blots were imaged on a Gel Doc™ XR System (Bio-Rad, Hercules, CA) 
via Chemiluminescence in the Blot dropdown settings. The exposure range was 
set from 1-40s exposure. All western blot images were exported as a publication 
quality .jpg file using Image Lab™ Software (Bio-Rad, Hercules, CA). Trans-Blot® 





secondary Ab conjugated to horseradish peroxidase (HRP), and the HRP 
activated by SuperSignal West Fempto Maximum Sensitivity Substrate (Thermo 
Fisher Scientific) solution. 
 
Bacterial Purified Protein Western Blot. 10µL of affinity purified recombinant 
proteins, of unknown concentration, from the M15[pREP4] clones I.B.’s were 
probed with a protein specific primary rabbit polyclonal antibody (pAb) at an 
optimal dilution ratio as follows: rabbit anti CatB 1:150, rabbit anti EglC 1:125, 
rabbit anti PPIase 1:420, rabbit anti TrxR 1:360. The primary Abs used for the 
cytosolic purified rPPIase-6xHis and rCatB-6xHis western blots were the same 
rabbit pAbs and dilutions just mentioned.  The secondary Ab, used for both the 
cytosolic and I.B. purified protein blots, was goat anti rabbit IgG-HRP 1:8,000. 
Image of the blot was captured at a 1s exposure.  
 
Fairbanks Quick Coomassie Whole Protein Stain of Cytocolic Purified 
Protein. The Fairbanks Quick Coomassie staining method (28) was used to 
detect whole protein content of cytosolic affinity purified rPPIase+6xHis and 
rCatB+6xHis elution fractions run on SDS gels. The gel was imaged on a Gel 
Doc™ XR System (Bio-Rad, Hercules, CA) via Coomassie Blue setting in the 
protein stain dropdown box. The image was exported as a publication quality .jpg 






EZQ® Whole Protein Stain of I.B. Purified Protein. Trans-Blot® Turbo™ PVDF 
membranes of  I.B. affinity purified elution fractions from the M15[pREP4] clones 
containing each of the 5 constructs, were analyzed by an adapted SYPRO® Ruby 
Protein Gel Stain (Life Technologies™, Carlsbad, CA) protocol using EZQ® 
Protein Quantitation (Life Technologies™, Carlsbad, CA) fluorescent dye. The 
EZQ® stained PVDF membranes were imaged on a Gel Doc™ XR System (Bio-
Rad, Hercules, CA) via SYPRO ruby setting in the protein stain dropdown 
settings. All EZQ® stain images were exported as a publication quality .jpg file 
using Image Lab™ Software (Bio-Rad, Hercules, CA). The PVDF membrane was 
placed in a polypropylene staining dish with 10% methanol and 7% acetic acid in 
ddH2O and incubated at RT for 15 min. The membrane was incubated in four 
changes of ddH2O, each for 5 min, and then immersed in EZQ
® fluorescent dye, 
and incubate for 15 min. at RT. Membrane was washed 6 times in ddH2O for 
each for 1min. with gentle rocking, and imaged under settings previously stated. 
The total protein in the TM3B6 and TM5A2 mAb Reactivity blots were also 
stained according to this protocol.   
 
Waking and Maintaining Mammalian Cells for Fusion. A week before the 
fusion, a vial of P3x63Ag.653 myeloma cells were removed from liquid nitrogen 
storage and grown in 15% complete RPMI at 37°C, with 5% CO2. J774.2 cells 





RPMI at 37°C, with 5% CO2. The myeloma cells and J774.2 cells were split every 
2 days in 15% complete RPMI prior to fusion to keep them in mid-log growth 
phase. For the ClonaCell®-HY fusion protocol, the P3x63Ag.653 myeloma cells 
were awoken and maintained using ClonaCell®-HY Pre-Fusion Medium (Medium 
A) in place of 15% complete RPMI. 
 
BALB/c Immunization, Boost, and Splenectomy. In preparation for the first 
round of traditional fusions, five BALB/c mice for each recombinant protein were 
immunized with 50ug of cytosolic lysate purified rPPIase+6xHis and rCatB+6xHis 
for a total of 10 immunizations. The rPPIase+6xHis and rCatB+6xHis proteins 
were emulsified in TiterMax® Gold adjuvant (CytRx Corporation, Los Angeles, 
CA) before immunizations were administered. For the ClonaCell®-HY fusion, five 
BALB/c mice were each immunized with 50ug of cytosolic lysate purified rPPIase 
emulsified in TiterMax® Gold adjuvant (CytRx Corporation, Los Angeles, CA). 
Polyclonal antibody (pAb) titers, from each mouse serum sample, were analyzed 
every two weeks by rabbit anti 6xHis/mouse pAb sandwich ELISA . The mice 
prepared for the first round of traditional fusions were labeled traditional-CatB-
Right1 (T-C-R1), traditional-PPIase-Right1 (T-P-R1), and traditional-PPIase-
Right2 (T-P-R2). At 6 weeks, T-P-R1 and T-P-R2 had high titers against 
rPPIase+6xHis, while T-C-R1 had lower titers. All three mice were boosted via 
I.V. with 10ug of their respective recombinant protein. T-C-R1 was boosted to try 





labeled ClonaCell®-HY-PPIase-Right 2 (CC-P-R2), immunized in preparation for 
the ClonaCell®-HY protocol, had high titers against rPPIase and was boosted via 
I.V. with 10ug of rPPIase. The serum from each mouse, for both protocols, was 
screened for specificity to native PPIase in A. fum cell lysate at week 6 and then 
again at 3 days post-boost. All mice were euthanized, 3 days post-boost, and a 
splenectomy was performed to harvest the splenocytes for fusion with myeloma 
cells. A second set of immunizations with rPPIase+6xHis and rCatB+6xHis were 
performed alongside the ClonalCell®-HY protocol using the exact immunization 
protocol for the traditional fusion, mentioned above, with the exception that 5 
BALB/c mice were immunized with rCatB+6xHis conjugated to KLH 
(rCatB+6xHis-KLH) instead of rCatB+6xHis as stated in the first immunization.  
 
6 Week Immunized and Post-Boost Mouse Serum Western Blot. 25µg of 
RPMI cultured A. fumigatus cell lysate (A. fum. Lys.) and rBipC+6xHis were 
probed with 1:120 dilutions of 6 week immunized T-C-R1, T-P-R1, and T-P-R2 
mouse serum. 3 day post-boost CC-P-R2, T-P-R1, and T-P-R2 mouse serum 
was probed using the same dilutions and samples. The 6 week and post-boost 
blots were detected with goat anti mouse IgG-HRP 1:3,000 secondary Ab. The 6 
week immunized and post-boost images for the T-C-R1, T-P-R1, and T-P-R2 
blots were captured at a 1s exposure. The post-boost image for the CC-P-R2 blot 





in the western blots was cultured, lysed, and supplied by Amanda Burnham-
Marusich and Breeana Hubbard in the Kozel lab.  
 
Rabbit anti 6xHis Sandwich ELISA Protocol. All ELISA’s (27) were conducted 
on the rabbit anti 6xHis Sandwich ELISA format. 250ng of rabbit anti 6xHis, in 
100mLs of PBS, was plated in a polystyrene 96wp and incubated overnight at 
RT. The plate was washed 3x with 300µLs of PBST-0.05% (PBS + 0.05% Tween 
20) and 100ng of recombinant protein in 100mLs of ELISA block buffer (PBST-
0.05% + 5% skim milk) was added to the wells. The plate was incubated at 37°C 
for 1hr 30min., and washed 3x with 300µLs of ELISA block buffer. Primary Ab, in 
100mLs of ELISA block buffer, was added to the wells and incubated at RT for 
1hr 30min., and washed 3x with 300µLs of ELISA block buffer. Secondary Ab, in 
100mLs of ELISA block buffer, was added to the wells and incubated at RT for 
1hr 30min. Plate was washed 3x with 300µLs of PBST-0.05%, 100µLs of TMB 
Substrate solution mix (Thermo Fisher Scientific, Waltham, MA) was added and 
incubated for 30min. at RT. 100 µLs of 1M H3PO4
 stop solution was added to 
each well and read at 450nm. ELISA data was analyzed with Gen5 software 
v1.07.5 (BioTek® Instruments Inc., Winnoski, VT).  
 
Mouse Serum Titration, Fusion Screening, and mAb Isotyping ELISA. A 





CC-P-R2 were plated as the primary Ab in the 6 week immunized mouse serum 
titration ELISA, followed by goat anti mouse IgG-HRP 1:3,000 as the secondary 
Ab. Pre-bleed serum of immunized mice was run in tandem with the 6 week 
immunized mouse serum as a negative control.  
 
100µL of each fusion well supernatant, with an unknown concentration of Ab, 
was plated as the primary Ab on a rabbit anti 6xHis ELISA. A 1:3,000 dilution, of 
goat anti mouse IgG-HRP, was plated as the secondary Ab. A 1:2,000 dilution of 
10mg/mL F26G3 B. anthracis mAb (41) was run as a negative control and T-P-
R2 mouse serum was run as a primary Ab, positive control in the fusion 
screening ELISA. 
 
A 1:2,000 dilution of 10mg/mL TM3B6 and TM5A2(pH3) were plated as the 
primary Ab in the TM3B6 and TM5A2(pH3) mAb isotype ELISA, followed by 
1:1,000 dilutions of goat anti mouse IgG1-HRP, IgG2a-HRP, IgG2b-HRP, IgG3-
HRP as the secondary Ab’s. A 1:2,000 dilution of 10mg/mL F26G3 B. anthracis 
mAb (41) was run as a negative control and a goat anti mouse IgG-HRP 1:3,000 







Traditional Splenocyte and Myeloma Fusion. The traditional fusion was 
carried out according to the Kohler, G., and Milstein, C. et. al protocol (40) with 
modifications listed below. P3x63Ag.653 myeloma cells were combined with 
pooled splenocytes from mouse T-P-R1 and T-P-R2, in a 50mL conical tube, and 
placed in a 37°C water bath. 1mL of PEG was gradually added to the cell mixture 
over a 30s period at 37°C with continual stirring. The mixture was stirred for an 
additional 30s and then 7mL of fresh RPMI was gradually added to the mixture 
over a 60s period. Next, 43mL of fresh RPMI was gradually added over a 90s 
period. The cell mixture was centrifuged at 400xg for 5min., resuspended in a 
final volume of 120mL of HAT media, and plated in peritoneal macrophage lined 
48 well plates (48wp). The 48wp were incubated at 37°C at 5% CO2 for 10 days, 
and 100µL of supernatant was removed from each well and analyzed for 
antibody production via Rabbit anti 6xHis/48wp sup. ELISA. The three highest 
titer wells (3B6, 4D1, and 5A2) from the 48wp, were plated out in 96 well plates 
(96wp) at 1 cell/well by limiting dilution with 15% J774.2 supernatant in a 200µL 
volume of HAT media. After 5 days, the hybridoma colonies were counted. One 
week later, 100µL of supernatant was analyzed via ELISA. A second traditional 
fusion was performed using rPPIase+6xHis immunized mouse splenocytes in 
accordance with the same traditional protocol as mention above. 
 
ClonaCell®-HY Splenocyte and Myeloma Fusion. The ClonaCell®-HY Fusion 





second traditional protocol fusion to compare the relative abundance of 
successfully fused clones and mAb production between the two protocols. The 
ClonaCell®-HY fusion was conducted using P3x63Ag.653 myeloma cells fused 
with splenocytes from mouse CC-P-R2 in accordance with manufacturer’s 
specifications. 
 
Cloning mAbs by Limiting Dilution. Cloning by limiting dilution, in a 96wp 
format, was performed in accordance with Staszewski et. al. protocol (75) in 
order to make sure that the probability of monoclonality was high. The probability 
of monoclonality follows a Poisson distribution, and requires that approximately 
33% of the wells be empty, increasing the likelihood that the hybridoma cells are 
monoclonal. A visual inspection was also done on each dilution well to make sure 
that 1 distinct cluster was present in the well. For the dilution, a 1 cell/200µL well 
concentration was calculated for hybridoma cells in a 120mL dilution media total 
dilution in five, 96wps (120mL dilution media consists of 96mL HAT + cells 
resuspended in 24mLs of J774.2 supernatant). Hybridoma colonies of interest 
were resuspended in the 120mL and immediately plated into five, 96wps at 1 
cell/200 µL, and incubated at 37°C, with 5% CO2 for 1 week. The hybridomas in 
the 48wp wells, selected for dilution, were split every 2 days and maintained in 
HAT media as backup wells. A second 1 cell/well dilution was performed 






Scale-Up and Purification of mAb Production. Stable hybridoma clones 
TM3B6 and TM5A2, having high mAb production, were selected from the second 
1 cell/well dilution wells. The clones were moved to 1mL of 15% complete 
media+20% J774.2 supernatant mixture in 48wp format and grown at 37°C with 
5% CO2, until confluent. Using fresh 15% complete media+20% J774.2 
supernatant each transfer, the cells were scaled up from the 48wp to a 24 well 
plate, a T25 cell culture flask, a T75 cell culture flask, a T175 cell culture flask, 
and finally 6x-T175 cell culture flasks as they became confluent in each culture 
format. The clone cells were then moved from the 6x-T175 flasks to a CELLine 
CL 1000 (INTEGRA Biosciences Corp., Hudson, NH) where they were 
maintained and harvested in accordance with the manufacturer’s specifications. 
CELLine CL 1000 supernatant containing mAbs were harvested weekly and 
stored at -20°C until 1-2L of supernatant was obtained. The 1-2L of TM3B6 and 
TM5A2 CELLine CL 1000 supernatant was thawed and purified over a protein A 
column, dialyzed in PBS, spin filter concentrated to 10mg/mL, aliquoted into 
cryovials, and stored in liquid nitrogen.    
 
TM3B6 and TM5A2(pH3) mAb Reactivity Western Blots. 350µg of A. fum. 
infected guinea pig serum {GP(+)},  344µg naïve guinea pig serum {GP (-)} with 
and without a 300ng rPPIase+6xHis spike, 7.4µg of A. fum. Lys., 7.34µg of C. 
albicans. Lysate (C. alb. Lys.) and 300ng of rPPIase+6xHis were probed with a 





Goat anti mouse IgG-HRP 1:3,000 was added as the secondary Ab. The 6 
images for the T-C-R1, T-P-R1, and T-P-R2 blots were captured at a 1s 
exposure. The images for the TM3B6 and TM5A2(pH3) mAb reactivity western 
blots were captured at a 1s exposure. The A. fum. Lys. and C. alb. Lys. used in 
the western blots was cultured, lysed, and supplied by Amanda Burnham-
Marusich and Breeana Hubbard in the Kozel lab, and the GP (+), and GP(-) were 
manufactured and supplied by ProSci Inc., San Diego, CA.  
 
Biacore® X100 mAb Binding Affinity Assays. TM3B6 and TM5A2 were diluted 
in HBS-buffer (HEPES buffered saline, pH7.4) to concentrations of both 
800µg/mL and 1600µg/mL each. The four samples were run using a Bioacore 
x100 (General Electric Healthcare, UK) on a CM5 chip, at 300s intervals, in 
succession from TM3B6 at 800µg/mL to 1600µg/mL, and then TM5A2 at 
800µg/mL to 1600µg/mL. The samples were also run in reverse orientation from 
TM5A2 to TM3B6 using the same concentrations previously mentioned. All 
sensorgram and Bioacore 100x data was analyzed using Biacore 100x 
Evaluation software V2.0.1 (General Electric Company, Fairfield, CT). 
 
LC MS-MS Analysis. 10µg of each protein, in 1x PBS, was submitted to Nevada 
Proteomics Center for LC MS-MS (36) analysis. The Nevada Genomics Center 





performed an NCBI and Broad Institute database comparison against the known 
protein sequences of each sample. The database comparison sequence data, of 
each recombinant protein, was exported into and analyzed using Scaffold™ v. 







Gene Construct Cloning, Sequence Verification, and Transformation. The 
PPIase, CatB, Eglc, Ecm33, and TrxR, gene constructs (Fig. 1a), previously 
assembled in the pQE-30Xa plasmid expression vector by Dr. Scott Filler’s Lab 
(Harbor UCLA), were transformed into NEB 5-alpha E. coli, grown in 1L cultures, 
DNA prepped via Maxiprep (Qiagen, Netherlands), and transformed into 
M15[pREP4] E. coli. A restriction analysis was conducted on each gene 
constructs in pQE-30Xa to verify that the correct construct and vector specific 
R.E. sites were present and, when cut, produce the predicted size DNA 
fragments. R.E.’s were used to make at least one cut in the gene construct and 
one in the plasmid vector. The restriction analysis showed that each intended 
gene construct in pQE-30Xa were likely present in the sample in the correct 
orientation, and had the predicted R.E. sites at the correct locale (Fig 3a).  
 
To prepare PPIase and TrxR for integration into the pYES3/CT yeast expression 
vector, as well as acquire functionality in protein production, flanking elements 
were added to each gene via PCR primers (Tab. 1 & 2). An EglC construct with 
the same flanking elements was synthesized by IDT for ligation into pYES3/CT. 
With each gene construct assembled (Fig. 1b), a subcloning digest was 
performed on the PPIase TrxR, and EglC gene constructs, as well as the 





The PPIase, TrxR, and EglC gene constructs were ligated into the pYES3/CT 
expression vector, transformed into NEB 5-alpha E. coli, grown in 1L cultures, 
DNA prepped via Maxiprep (Qiagen, Netherlands), and transformed into INVSc1 
yeast. A R.E. digest and colony PCR were performed to screen transformed NEB 
5-alpha for each pYES3/CT plasmid construct, as well as, verify that the 
construct and vector were the correct sizes and had retained the flanking NotI 
and HindIII restriction sites (Fig. 3b-c).     
 
Sanger sequencing (68) was conducted, by the Nevada Genomics Center, to 
determine if the EglC, PPIase, and TrxR constructs in pYES3/CT, as well as the 
entire plasmid itself, maintained their correct sequences, and the constructs had 
proper orientation within the vector. EglC, PPIase, CatB, Ecm33 and TrxR 
constructs in pQE-30Xa were also sequenced to determine correct sequences, 
and proper construct orientation within the vector. All the gene constructs 
sequences in pQE-30Xa and pYES3/CT were verified (data not shown).  
 
A. fumigatus Recombinant Protein Antigen Production and Purification. 
The M15[pREP4] clones of EglC, PPIase, CatB, and TrxR constructs in pQE-
30Xa produced recombinant 6xHis tagged protein in I.B.’s (Fig. 4a-b). The 
PPIase and CatB clones  produced recombinant protein in the cytosolic fraction 





Multiple attempts with varied conditions were made to produce recombinant 
protein in the INVSc1 clones of PPIase, TrxR, and EglC constructs in pYES3/CT 
with no success (data not shown). The PPIase, TrxR, and EglC constructs in 
pYES3/CT were then sent to NeoBioLabs for commercial protein production in S. 
cerevisiae. The commercial production was unsuccessful. rPPIase+6xHis and 
rCatB+6xHis from the cytosolic fraction of the M15[pREP4] were affinity purified, 
dialyzed into PBS, concentrated, quantitated, and LC MS-MS analyzed by the 
Nevada Proteomics Center. The rCatB+6xHis amino acid sequence was 
positively identified when referenced to both the NCBI and Broad Institute 
database. The rPPIase+6xHis amino acid sequence came up positive in the 
Broad Institute database search, but was identified as chain A of A. fum 
cyclophilin when referenced to NCBI (data not shown). A portion of purified 
rPPIase+6xHis and rCatB+6xHis was cleaved with Factor Xa in order to remove 
the 6xHis tag.     
 
Immunized Mouse Serum pAb Reactivity to Antigen. Serum was collected 
from all pre-immunized BALB/c mice as a means of comparison to the post-
immunized mouse serum.  Both rPPIase+6xHis and rCatB+6xHis purified from 
the cytosolic fraction of the M15[pREP4] were emulsified in TiterMax® Gold 
adjuvant (CytRx Corporation, Los Angeles, CA), to elicit a greater immune 
response to the proteins, and the 5 BALB/c mice per protein were immunized. 





rabbit anti 6xHis sandwich ELISA as the primary Ab. The 6 week post-immunized 
mouse serum from T-C-R1, T-P-R1, and T-P-R2 showed the greatest reactivity 
to recombinant protein, out of the immunized mice groups, and maintained good 
titres having an OD (450 nm) near 1.0 at an approximate 1:5,000 dilution (Fig. 
5a). The T-C-R1, T-P-R1, and T-P-R2 pre-bleed serum showed no reactivity to 
recombinant protein (Fig. 5b). The 6 week T-C-R1, T-P-R1, and T-P-R2 serum 
was run on a western blot with A. fumigatus lysate and rBipC+6xHis tag, to 
determine if the pAb in the mouse serum was reactive with the native A. 
fumigatus protein and/or the recombinant 6xHis tag of a foreign protein. The 6 
week T-C-R1 mouse serum detected the rBipC-6xHis band, at the expected 
40KDa, but was unable to detect CatB at the expected 83KDa in the A. fumigatus 
lysate, while the 6 week T-P-R1 and T-P-R2 mouse serum detected a 21KDa 
band, the expected molecular weight (MW) of native PPIase, in the A. fumigatus 
lysate (Fig 6a). The T-P-R1 and T-P-R2 mice were then boosted with 
rPPIase+6xHis, lacking adjuvant, in preparation for a traditional fusion. The T-C-
R1 mouse was not boosted, as there was no Ab in the mouse serum that 
detected native CatB. The post-boost T-P-R1 and T-P-R2 mouse serum detected 
a 21KDa band, the expected MW of PPIase, in the A. fum cell lysate and did not 
detect anything in the rBipC+6xHis (Fig 6b).   
 
Factor Xa cleaved rPPIase and rCatB were emulsified in TiterMax® Gold 





were immunized. The 6 week post-immunized serum for all 5 rCatB immunized 
BALB/c mice had no reactivity to rCatB+6xHis screening, by rabbit anti 6xHis 
ELISA, and a fusion was not pursued. The 6 week post-immunized mouse serum 
from CC-P-R2 had good reactivity to recombinant protein, and maintained good 
titres having an OD (450 nm) well above 1.0 at an approximate 1:5,000 dilution 
(Fig. 7a). The 6 week immunized CC-P-R2 was run on a western blot (data not 
shown), and boosted, using the same procedure previously mentioned, in 
preparation for the ClonaCell®-HY fusion. The post-boost CC-P-R1 mouse serum 
detected the 21KDa band in the A. fum cell lysate and the rBipC+6xHis lane 
showed no reactivity (Fig 7b). 
 
Fusion Screening and mAb Isotyping. The traditional fusion was performed 
and screened by ELISA. 5A2, 3B6, and 4D1 were the fusion wells with the 
highest affinity for rPPIase+6xHis, and thus were selected for cloning by limiting 
dilution. Fusion wells 3B6 and 5A2, continued to produce Ab with good affinity to 
rPPIase-6xHis through the cloning process while 4D1 ceased producing Ab 
specific to the recombinant protein and was no longer maintained as a clone (Fig. 
8a). After two rounds of cloning, the mAbs were named TM3B6 and TM5A2 and 






The TM3B6 and TM5A2(pH3) were purified, concentrated, then isotyped by 
ELISA. TM3B6 and TM5A2(pH3) had absorbance values, comparable to the goat 
anti mouse IgG-HRP positive control, indicating that they were isotype IgG1 and 
IgG2a respectively (Fig. 8b) During the supernatant collection process for 
purification, some TM3B6 supernatant was most likely pooled into TM5A2, as 
seen later in the pH 6 elution profile of TM5A2 (data not shown). After the 
purification discrepancy, the scale-up supernatant of TM5A2 was isotyped to be 
IgG2a as seen in the pH3 fraction of the purification (data not shown).  
 
Epitope Determination. An epitope affinity assay was conducted on purified 
TM3B6 and TM5A2(pH3) to determine if each mAb had a shared epitope or 
specific epitopes on rPPIase+6xHis. TM3B6 and TM5A2(pH3) samples were run 
in succession over a CM5 chip containing rPPIase+6xHis in the stationary phase. 
TM3B6 was run at 800µg and 1600µg, in order to make sure the chip was 
saturated, and is seen as the first two peaks appearing, followed by TM5A2 at 
800µg and 1600µg seen as the last two peaks (Fig. 9). The saturation of the two 
TM3B6 peaks can be observed at approximately 550RUs. Following the TM3B6 
peaks, are the two TM5A2 peaks that saturate at approximately 650RUs. This 
upward shift is indicative of multiple epitopes as the TM5A2(pH3) causes an 
upward RU shift above the baseline of the TM3B6 mAb concentrations. The 
TM5A2 and TM3B6 mAbs, with the same concentrations, were run over the 





saturation at approximately 600RUs for 150s each, but each peak begins to 
decline due to the mAb dissociation. The TM3B6 peaks also saturate at 600RUs, 
and no RU upward shift is observed. This is because the TM5A2 mAbs do not 
have a great enough affinity for the rPPIase+6xHis to remain bound in order to 
see the upward shift seen in Fig. 9.  
 
TM3B6 and TM5A2(pH3) mAb Reactivity Panel. TM3B6 and TM5A2 were 
probed against a panel of samples to see if the purified mAbs could detect native 
PPIase in comparison with the rPPIase+6xHis. In western blot format, the TM3B6 
and TM5A2 could detect the 300ng of rPPIase+6xHis in both the stand-alone and 
spiked guinea pig serum, but were unable to detect the presence of native 














The recent advent of immunosuppressive therapies and the prevalence of 
diseases like HIV/AIDS and leukemia have greatly increased the incidence of IA 
infections in immunocompromised patients, especially those in the ICU (1, 16, 
24, 60, 67, and 80). IA has also become a major problem for non-neutropenic 
patients (47). Though non-neutropenic patients retain high levels of neutrophils 
necessary for innate immune function, the phagocytic ability is hindered, and 
these patients usually succumb to a severe inflammatory response (19). In 
consideration of these issues, a proven, rapid and reliable diagnostic is needed, 
as a prompt detection and positive determination is crucial for IA infected 
patient’s survival, especially non-hematological patients (35).   
 
MAb diagnostic methods have had increased success, compared to earlier 
developed diagnostic approaches such as radiological analysis and BALF 
cultures, but have also encountered complications regarding cross-reactivity with 
other fungal species and a lack of sensitivity (38, 45, and 83). Most of the recent 
mAb immunodiagnostics have been based on the detection of GM circulating in 
IA infected serum (44, 61). The GM based mAb assays have been associated 
with high variability in sensitivity and have also had issues with false positives 
triggered by fungal derived antibiotics, bacterial GM, as well as GM found in food 





mAb detection assays, there is a need for an IA immunodiagnostic test that 
utilizes mAbs aimed against alternate epitopes. 
 
To address the need for mAbs directed against GM alternative epitopes, for 
potential diagnostic purpose, our lab employed a technique called In vivo 
Microbial Antigen Discovery (InMAD) to screen for potential antigen targets 
circulating in serum, specifically mouse serum (57). Using this technique our lab 
discovered a series of circulating immunogenic proteins and prioritized the list of 
protein antigens based on their immunogenicity (13). The candidates that we 
chose to pursue as potential A. fum antigen targets for mAb production were 
peptidyl-prolyl cis-trans isomerase (PPIase), glucan endo-1,3-beta-glucosidase 
(Eglc), Extracellular mutant protein 33 (Ecm33), thioredoxin reductase (TrxR) and 
catalase B (CatB). Immunogenic peptide segments of each of these proteins, 
non-homologous to other fungal and bacterial species, were previously tested for 
pAb reactivity in IA animal models, but whole protein immunizations had not been 
employed (13).  
 
All of the five genes, coding for the previously determined proteins of interest, 
were assembled into functional plasmid constructs by our lab, our collaborators, 
and commercial assembly for whole protein production in bacterial and yeast 
systems (Fig. 1 & 3).  Recombinant EglC, CatB, PPIase, and TrxR protein was 





in mouse immunizations, as the protein is denatured in the I.B. extraction 
process. The use of natured protein for immunizations was desired to ensure that 
the mouse’s immune system was exposed to as close to native conformations as 
possible. Recombinant CatB and PPIase were successfully produced in the 
cytosolic fractions of the bacteria (Fig 4c-d), which does not require denaturing 
conditions, and were used for immunizations. Ecm33 did not produce 
recombinant protein in either fraction (Data not show). Production of each of the 
five proteins in S. cerevisiae was pursued with the rational that A. fum is 
phylogenetically closer to S. cerevisiae than any bacterial system and can 
incorporate post-translational modifications that bacteria are unable to. Attempts 
to produce protein in S. cerevisiae by our lab as well as commercial, were 
unsuccessful (data not shown).  
 
The mouse sera from each rPPIase+6xHis 6 week post-immunization and post-
boost had good reactivity against recombinant protein in ELISA and western blot 
format, were able to detect native protein in the A. fum lysate, and had no 
reactivity to rBipC+6xHis. The rCatB+6xHis 6 week post-immunization serum had 
weak reactivity towards recombinant protein in ELISA format, detected the 
rBipC+6xHis, but was unable to detect native protein in the A. fum lysate (Fig. 5 
& 6). It is therefore likely, that the mouse immunized with rCatB+6xHis made pAb 
to the 6xHis tag, while the mice immunized with rPPIase+6xHis made pAb 





A successful fusion was performed, screened, and the top three producing wells 
(4D1, 3B6, and 5A2) were isolated for scale-up production (Fig. 8a). During the 
scale-up process, the isolated 4D1 ceased to produce mAbs and was pursued no 
further. Purified TM3B6 and TM5A2(pH3) were isotyped as IgG1 and IgG2a, 
respectively, and an epitope affinity determination assay was performed (Fig 8b). 
Each mAb was ascertained to have specific epitopes (Fig. 9 & 10), which is 
desirable, as they can be incorporated into a lateral flow immunoassay (LFI, aka 
LFD) with one mAb in the capture phase and the other in the indicator phase.  
An alternate fusion protocol, ClonaCell-HY, was attempted using an immunized 
mouse with reactivity comparable to the mice in the traditional fusion protocol 
(Fig. 7), but the fusion was unsuccessful (data not shown). 
       
TM3B6 and TM5A2(pH3) showed good reactivity against recombinant PPIase, 
both stand-alone and in serum, but were unable to detect native protein in its 
host organism (Figure 11). The goals for future this specific work on mAb 
development against immunogenic A. fum proteins is to, further investigate 
obstacles of protein production in bacterial and yeast systems and improve 
fusion techniques to increase the number of stable clones that produce mAbs 
reactive to native protein. The overall goal remains that of developing an IA 
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Table 2. Primers  
Primer Name Application Sequence 5' → 3' 
Catalase F K3Koz 5' Element Additions  GGTGGTACCAAAAAAATGCGTCTCAC 
Catalase G-F  Cloning CatB ATGCGTCTCACGTTCATCCCC 
Catalase G-R  Cloning CatB GTGATCCACGGGAAACCGG 
Catalase R N1Xa 3' Element Additions  TTTGCGGCTTACGACCTTCAATGT 
Catalase R Xa 3' Element Additions  ACGACCTTCAATGTGATCCACGGGAA 
Catalase-Ecm33-Eglc R N1 3' Element Additions  TTTGCGGCCGCTTACGACCTTCAAT 
Ecm33 & Eglc N1Xa 3' Element Additions  TTTGCGGCCGCTTACGACCTTCAATCA 
Ecm33 F H3Koz 5' Element Additions GGTAAGCTTAAAAAAATGGCTTTCCTC 
Ecm33 G-F  Cloning Ecm33 ATGGCTTTCCTCAAATACGCTCTC 
Ecm33 G-R  Cloning Ecm33 CAAAACGTACTGCACCAGAGCTC 
Ecm33 R Xa 3' Element Additions  ACGACCTTCAATCAAAACGTACTGCAC 
Eglc F H3Koz 5' Element Additions  GGTAAGCTTAAAAAAATGCAATTCACA 






Table 2. Primers  
Eglc G-R  Cloning EglC CAGGGCAGCCAGAGCG 
Eglc R Xa 3' Element Additions  ACGACCTTCAATCAGGGCAGCCA 
Eglc-seq-F-1321 Sequencing Eglc+pYES3/CT GGTGCAGTAGTAGCTGTATGCC 
Eglc-seq-F-247 Sequencing Eglc+pYES3/CT GCTATTCCCGCTGCAATAACTG 
Eglc-seq-F-776 Sequencing Eglc+pYES3/CT CCGTAGCCAACTTGGCAAATGC 
ppcti F H3Koz 5' Element Additions  GGTAAGCTTAAAAAAATGTCTCAGGTC 
PPCTI Foward Cloning PPIase ATGTCTCAGGTCTTCTTCGA 
ppcti R N1Xa 3' Element Additions TTTGCGGCCGCTTACGACCTTCAATCA 
PPCTI Reverse Cloning PPIase TTACAGCTCACCACAGTTGA 
pQE-30Xa F prime (2)  Sequencing pQE-30Xa  GGATCTGGCTCTGGATCT 
pQE-30Xa R prime (2)  Sequencing pQE-30Xa  TGGATCTATCAACAGGAGTCCAA 
pYES 3 R Primer Sequencing  ACATGATGCGGCCCTCTAGG 
pYES 3 T7 F Primer Sequencing  ACTAGCAGCTGTAATACGACTCACTAT 
pYES3/CT-Ins-R-874 Sequencing pYES3/CT  CATGCGTACACGCGTCTGTAC 
pYES3/CT-Vec-F-1208 Sequencing pYES3/CT  GCGTTGCTGGCGTTTTTCC 
pYES3/CT-Vec-F-1721 Sequencing pYES3/CT  GGTAGCTCTTGATCCGGCAAAC 
pYES3/CT-Vec-F-194 Sequencing pYES3/CT  GCAGTAACCTGGCCCCACAAAC 
pYES3/CT-Vec-F-2205 Sequencing pYES3/CT  CTTTATCCGCCTCCATCCAGTC 
pYES3/CT-Vec-F-2708 Sequencing pYES3/CT  CGATGTAACCCACTCGTGCAC 
pYES3/CT-Vec-F-3190 Sequencing pYES3/CT  GGTGAAAGTTTGCGGCTTGC 
pYES3/CT-Vec-F-3692 Sequencing pYES3/CT  GGACTGACGCCAGAAAATGTTGG 
pYES3/CT-Vec-F-4179 Sequencing pYES3/CT  CGAATACGCTTTGAGGAGATACAGC 
pYES3/CT-Vec-F-4437 Sequencing pYES3/CT  GCGTTTCCATCTTGCACTTCAATAGC 
pYES3/CT-Vec-F-4942 Sequencing pYES3/CT  CGTTTACTGATTACTAGCGAAGCTGCG 
pYES3/CT-Vec-F-5332 Sequencing pYES3/CT  GGAAGCGGTATTCGCAATGGG 
pYES3/CT-Vec-F-5724 Sequencing pYES3/CT  GAGCTTGACGGGGAAAGC 
pYES3/CT-Vec-F-720 Sequencing pYES3/CT  CCTAGAGGGCCGCATCATGTAATTAG 
Thiored F H3Koz 5' Element Additions GGTAAGCTTAAAAAAATGTCGATCGG 










Figure 1. Gene construct designs with flanking elements. a. The template 
displays the 5’ flanking 6xHis and Factor Xa protease sites for each bacterial 
gene construct  and the R.E. sites flanking the gene insert. b. The template for 
each gene construct in pYES3/CT. The 5’ kozak and Hind III site, as well as the 









                                    
 
Figure 2. Diagram of Rabbit anti 6xHis sandwich ELISA configuration. This 
format was used for every ELISA in this study. 
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Figure 3. Restriction analysis digest of gene constructs in pQE-30Xa and a R.E. 
digest with colony PCR of gene constructs in pYES3/CT. a. The R.E. digests 
produced the predicted number and size of DNA fragments in all of the 5 
restriction analyses shown in parenthesis next to each labeled construct. The 
23bp fragment for CatB-pQE-30Xa was not visible on the gel (lane 6) b. A R.E. 
digests verifying correct R.E. sites and successful ligation of the three constructs 
in pYES3/CT. The digested linear pYES3/CT (5.9Kb) and the gene construct’s 
lower bands can be observed at their expected lengths shown on the left. c. 
Bacterial colony PCR of the three gene constructs in pYES3/CT. The construct 








1: TrxR PCR  
2: EglC PCR  
3: PPIase PCR 
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1: 1 Kb Plus DNA Ladder  
2: EglC-pQE-30Xa (3.4Kb, 746bp and 673bp) 
3: Ecm33-pQE-30Xa (3.8Kb and 870bp) 
4: TrxR-pQE-30Xa (4.3Kb and 208bp) 
6: CatB-pQE-30Xa (4.8Kb, 519bp, 274bp and 23bp) 
5: PPIase-pQE-30Xa (3.3Kb, 673bp and 236bp) 
     5Kb —   
     2Kb —   
      1Kb —   
 
 300bp —   
  100bp —   
 
 500bp —   
 






                         
Figure 4. Affinity purified recombinant protein from M15[pREP4] clones western 
blots and whole protein analysis. a. Recombinant protein from I.B. purified 
fraction and their MWs labeled on the left. b. A total protein EZQ® stain of the 
recombinant protein from I.B. purified fraction. c. Recombinant protein from the 
cytosolic purified fraction and their MWs. d. A Fairbank’s total protein stain 
corresponding to the recombinant protein from the cytosolic purified fraction with 
their MWs displayed on the left.  
1 2  3 4 
a. and b. 
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Figure 5. 6 week post-immunization and pre-bleed mouse serum titration ELISA. 
a. Reactivity of primary pAb in T-P-R1, T-P-R2, and T-C-R1 mouse serum, to 
rPPIase+6xHis, at specific dilutions. b. Mouse pre-bleed serum negative control 
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Figure 6. 6 week post-immunization and post-boost mouse serum probed against 
A. fum. cell lysate and rBipC-6xHis western blots a. 6 week T-C-R1 post-
immunization mouse serum detecting a 40KDa band in lane 2, the expected MW 
of BipC, and no reactivity in the A. fum cell lysate in lane 1. 6 week T-P-R1 and 
T-P-R2 post-immunization mouse serum each detecting 21KDa bands in lane 1, 
the expected MW of PPIase. b. The post-boost T-P-R1 and T-P-R2 mouse 
serum detecting a 21KDa band each in lane 1.  
 40KDa —   
 
1 2 1 2 
T-C-R1 T-P-R1 T-P-R2 
2: rBipC+6xHis  
1: A. fum. Lys. 
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Figure 7. 6 week post-immunization and pre-bleed mouse serum ELISA and 
post-boost western blot. a. Reactivity of CC-P-R1 mouse serum, to 
rPPIase+6xHis, at specific dilutions, and pre-bleed serum negative control. b. 
The post-boost CC-P-R1 mouse serum detection of a 21KDa band, the expected 
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Figure 8. Fusion well screening and purified mAb isotype ELISAs. a. Reactivity of 
48wp fusion well supernatant, T-P-R2 6 week post-immunized mouse serum (+ 
control) and a F26G3 B. anthracis mAb (- control). b. Reactivity of isotype 
specific secondary Abs against purified mAbs. Goat anti mouse IgG-HRP and a 
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Figure 9. TM3B6 and TM5A2(pH3) epitope affinity determination chromatogram. 
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Figure 10. Reverse TM5A2(pH3) and TM3B6 epitope affinity determination 
chromatogram. Each corresponding peak is labeled with the mAb type and 
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Figure 11. TM3B6 and TM5A2(pH3) reactivity against a panel of guinea pig 
serum, fungal lysates, and rPPIase+6xHis in western blot format and whole 
protein stain analysis. a. TM3B6 detected 21KDa, expected MW of PPIase, and 
unknown 50KDa bands in the naïve guinea pig spiked serum and the 
rPPIase+6xHis. All other sample lanes were unreactive. b. Total protein EZQ® 
stain of TM3B6 probed blot. c. TM5A2(pH3) detected 21KDa bands in the naïve 
guinea pig spiked serum and the rPPIase+6xHis. All other sample lanes were 
unreactive. d. Total protein EZQ® stain of TM5A2(pH3) probed blot 
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